Silencing RPL9 promotes malignant proliferation in breast cancer cells
We identified and constructed a 9-RBP based scoring model and a clinical prognostic nomogram for accurately predicting the survival probability and assessing the tumor microenvironment of patients with BRCA. Moreover, our findings firstly demonstrated that RPL9 downregulation correlated with poor clinical outcomes and functionally drives tumor cell proliferation, establishing it as a potential therapeutic target and prognostic biomarker for BRCA.
Authors
- Yuxuan Song
- Junze Dai
- R. Liu
- Xudong Zhu
- Heng Zhang (ORCID: https://orcid.org/0000-0002-0103-2173)
- Xin Wang (ORCID: https://orcid.org/0000-0002-7296-9406)
- Yefu Liu
- Tong Zhu
- Dingye Zhang
- Wenxin Li
- Hailin Tang
- Zhaohu Shi
Institutions
- Sun Yat-sen University (CN)
- Dalian Medical University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Jiangjin Central Hospital (CN)
- Liaoning Cancer Hospital & Institute (CN)
- China Medical University (CN)
Publication Details
- Journal
- International Journal of Immunopathology and Pharmacology
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1177/03946320261422055
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00